Endogenous opioid peptides in pregnancy.

Area of Science:

• Endocrinology
• Reproductive Biology
• Neuroscience

Background:

• Endogenous opioid peptides play crucial roles in physiological regulation.
• Pregnancy involves significant hormonal adaptations, including changes in the hypothalamic-pituitary-adrenal (HPA) axis.
• Beta-lipotrophin (beta-LPH) and its derivatives, such as beta-endorphin, are key components of the pro-opiomelanocortin (POMC) system.

Purpose of the Study:

• To investigate the dynamic changes in plasma levels of beta-endorphin, met-enkephalin, and N-terminal beta-lipotrophin (N-LPH) during normal human pregnancy.
• To correlate these changes with gestational age and understand their implications for maternal physiology.

Main Methods:

• Plasma samples were collected from 116 pregnant women across gestation (8-41 weeks).
• Radioimmunoassay techniques were employed to quantify beta-endorphin-like immunoreactivity (C-LPH), N-LPH, and met-enkephalin.
• Statistical analysis was performed to assess trends and significance.

Main Results:

• Plasma beta-endorphin-like immunoreactivity and N-LPH levels demonstrated a progressive increase throughout gestation, reaching peak concentrations at term.
• Plasma met-enkephalin immunoreactivity showed no significant alteration during the course of pregnancy.
• These findings suggest a coordinated increase in adrenocorticotrophin (ACTH)/beta-LPH and beta-endorphin secretion during pregnancy.

Conclusions:

• The observed rise in beta-endorphin and N-LPH supports an enhanced POMC system activity in late pregnancy.
• The stable met-enkephalin levels indicate its independent regulation, likely from a separate precursor, during gestation.
• These hormonal shifts may contribute to maternal adaptations during pregnancy and labor.